Novel therapy for the treatment of optic neuropathies by inhibition of semaphorin3A

A Spanish research centre, has jointly developed with a Israeli university, a family of compounds able to inhibit Semaphorin3A fostering nerve regeneration after injury. These compounds can be useful for treatment of ischemic events such as stroke, glaucoma and other optical nerve and retina insults. Biotech or pharmaceutical companies are sought for license agreement and/or research collaboration to perform preclinical assays.
Cooperación Tecnológica
Enlace: Novel therapy for the treatment of optic neuropathies by inhibition of semaphorin3A